|
1
|
Riddell IA: Cisplatin and oxaliplatin: Our
current understanding of their actions. Met Ions Life Sci.
18:2018.PubMed/NCBI
|
|
2
|
Formica V, Zaniboni A, Loupakis F and
Roselli M: Noninferiority of three months versus six months of
oxaliplatin-based adjuvant chemotherapy for resected colon cancer.
How should IDEA findings affect clinical practice. Int J Cancer.
143:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubbia-Brandt L, Audard V, Sartoretti P,
Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane
O, Chaussade S, et al: Severe hepatic sinusoidal obstruction
associated with oxaliplatin-based chemotherapy in patients with
metastatic colorectal cancer. Ann Oncol. 15:460–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duwe G, Knitter S, Pesthy S, Beierle AS,
Bahra M, Schmelzle M, Schmuck RB, Lohneis P, Raschzok N, Öllinger
R, et al: Hepatotoxicity following systemic therapy for colorectal
liver metastases and the impact of chemotherapy-associated liver
injury on outcomes after curative liver resection. Eur J Surg
Oncol. 43:1668–1681. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robinson SM, Mann J, Vasilaki A, Mathers
J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX
induced sinusoidal obstruction syndrome in a murine chemotherapy
model. J Hepatol. 59:318–326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chun YS, Laurent A, Maru D and Vauthey JN:
Management of chemotherapy-associated hepatotoxicity in colorectal
liver metastases. Lancet Oncol. 10:278–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin Y, Li Y, Hu X, Liu Z, Chen J, Lu Y,
Liu J, Liao S, Zhang Y, Liang R, et al: The hepatoprotective role
of reduced glutathione and its underlying mechanism in
oxaliplatin-induced acute liver injury. Oncol Lett. 15:2266–2272.
2018.PubMed/NCBI
|
|
8
|
Issa D, Patel V and Sanyal AJ: Future
therapy for non-alcoholic fatty liver disease. Liver Int. 38(Suppl
1): S56–S63. 2018. View Article : Google Scholar
|
|
9
|
Marchesini G, Bugianesi E, Forlani G,
Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N,
Melchionda N and Rizzetto M: Nonalcoholic fatty liver,
steatohepatitis, and the metabolic syndrome. Hepatology.
37:917–923. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fiorucci S, Biagioli M and Distrutti E:
Future trends in the treatment of non-alcoholic steatohepatitis.
Pharmacol Res. 134:289–298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martinez MA, Vuppalanchi R, Fontana RJ,
Stolz A, Kleiner DE, Hayashi PH, Gu J, Hoofnagle JH and Chalasani
N: Clinical and histologic features of azithromycin-induced liver
injury. Clin Gastroenterol Hepatol. 13:369–376e3. 2015. View Article : Google Scholar
|
|
12
|
Lu Y, Wang X, Yan W, Wang H, Wang M, Wu D,
Zhu L, Luo X and Ning Q: Liver TCRγδ(+) CD3(+) CD4(−) CD8(−) T
cells contribute to murine hepatitis virus strain 3-induced hepatic
injury through a TNF-α-dependent pathway. Mol Immunol. 52:229–236.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Masarone M, Rosato V, Dallio M, Gravina
AG, Aglitti A, Loguercio C, Federico A and Persico M: Role of
oxidative stress in pathophysiology of nonalcoholic fatty liver
disease. Oxid Med Cell Longev. 2018:95476132018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Green CJ, Parry SA, Gunn PJ, Ceresa CDL,
Rosqvist F, Piché ME and Hodson L: Studying non-alcoholic fatty
liver disease: The ins and outs of in vivo, ex vivo and in vitro
human models. Horm Mol Biol Clin Investig. Aug 11–2018.Epub ahead
of print. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koek GH, Liedorp PR and Bast A: The role
of oxidative stress in non-alcoholic steatohepatitis. Clin Chim
Acta. 412:1297–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Y, Dong H, Thompson DC, Shertzer HG,
Nebert DW and Vasiliou V: Glutathione defense mechanism in liver
injury: Insights from animal models. Food Chem Toxicol. 60:38–44.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Del Campo JA, Gallego P and Grande L: Role
of inflammatory response in liver diseases: Therapeutic strategies.
World J Hepatol. 10:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao B: Hepatoprotective and
anti-inflammatory cytokines in alcoholic liver disease. J
Gastroenterol Hepatol. 27(Suppl 2): S89–S93. 2012. View Article : Google Scholar
|
|
19
|
Yano A, Higuchi S, Tsuneyama K, Fukami T,
Nakajima M and Yokoi T: Involvement of immune-related factors in
diclofenac-induced acute liver injury in mice. Toxicology.
293:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rutherford A and Chung RT: Acute liver
failure: Mechanisms of hepatocyte injury and regeneration. Semin
Liver Dis. 28:167–174. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mittal M, Siddiqui MR, Tran K, Reddy SP
and Malik AB: Reactive oxygen species in inflammation and tissue
injury. Antioxid Redox Signal. 20:1126–1167. 2014. View Article : Google Scholar :
|
|
22
|
Zhang X, Zhang JH, Chen XY, Hu QH, Wang
MX, Jin R, Zhang QY, Wang W, Wang R, Kang LL, et al: Reactive
oxygen species-induced TXNIP drives fructose-mediated hepatic
inflammation and lipid accumulation through NLRP3 inflammasome
activation. Antioxid Redox Signal. 22:848–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deng Y, Ren X, Yang L, Lin Y and Wu X: A
JNK-dependent pathway is required for TNFalpha-induced apoptosis.
Cell. 115:61–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Wetering S, van Buul JD, Quik S, Mul
FP, Anthony EC, ten Klooster JP, Collard JG and Hordijk PL:
Reactive oxygen species mediate Rac-induced loss of cell-cell
adhesion in primary human endothelial cells. J Cell Sci.
115:1837–1846. 2002.PubMed/NCBI
|
|
25
|
Fabregat I and Caballero-Diaz D:
Transforming growth factor-β-induced cell plasticity in liver
fibrosis and hepatocarcinogenesis. Front Oncol. 8:3572018.
View Article : Google Scholar
|
|
26
|
Kisseleva T and Brenner DA: Role of
hepatic stellate cells in fibrogenesis and the reversal of
fibrosis. J Gastroenterol Hepatol. 22(Suppl 1): S73–S78. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin W, Tsai WL, Shao RX, Wu G, Peng LF,
Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY and Chung RT:
Hepatitis C virus regulates transforming growth factor beta1
production through the generation of reactive oxygen species in a
nuclear factor kappaB-dependent manner. Gastroenterology.
138:2509–2518. 2518.e12010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tan Z, Qian X, Jiang R, Liu Q, Wang Y,
Chen C, Wang X, Ryffel B and Sun B: IL-17A plays a critical role in
the pathogenesis of liver fibrosis through hepatic stellate cell
activation. J Immunol. 191:1835–1844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan L and Kaplowitz N: Glutathione in
liver diseases and hepatotoxicity. Mol Aspects Med. 30:29–41. 2009.
View Article : Google Scholar
|
|
30
|
Wang J, Chen Y, Gao N, Wang Y, Tian Y, Wu
J, Zhang J, Zhu J, Fan D and An J: Inhibitory effect of glutathione
on oxidative liver injury induced by dengue virus serotype 2
infections in mice. PLoS One. 8:e554072013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peter C, Braidy N, Zarka M, Welch J and
Bridge W: Therapeutic approaches to modulating glutathione levels
as a pharmacological strategy in Alzheimer's disease. Curr
Alzheimer Res. 12:298–313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gross CL, Giles KC and Smith WJ:
L-oxothiazolidine 4-carboxylate pretreatment of isolated human
peripheral blood lymphocytes reduces sulfur mustard cytotoxicity.
Cell Biol Toxicol. 13:167–173. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zou X, Wang Y, Peng C, Wang B, Niu Z, Li Z
and Niu J: Magnesium isoglycyrrhizinate has hepatoprotective
effects in an oxaliplatin-induced model of liver injury. Int J Mol
Med. 42:2020–2030. 2018.PubMed/NCBI
|
